The statistics are sobering and undeniable — African American men develop prostate cancer at twice the rate of white men and are more likely to die from the disease. This reality makes understanding ...

For decades, men with prostate cancer were routinely advised against testosterone replacement therapy (TRT), even if they had ...

Talazoparib plus enzalutamide met the primary endpoint in TALAPRO-2, lowering radiographic progression or death risk by 37% versus enzalutamide, with median rPFS not reached. Efficacy signals extended ...

Patients with recurring prostate cancer who were treated with a new PSMA-targeted radioligand therapy before stereotactic body radiotherapy (SBRT) went more than twice as long without their disease ...

A large analysis of two major clinical trials has found that the spread of prostate cancer can be detected on imaging scans even when biomarkers remain stable in patients treated with androgen ...

Add Yahoo as a preferred source to see more of our stories on Google. For men facing the return of prostate cancer, a new combination therapy may offer a much longer break before the disease comes ...

Prostate cancer is one of the most frequently diagnosed cancers in men yet is often highly treatable when detected early. It originates in the prostate gland, located between the bladder and the penis ...

A targeted focal therapy can now help prostate cancer patients as it promises same outcomes with fewer side effects than ...

July 22 (Reuters) - Pfizer said on Wednesday the U.S. Food and Drug Administration had granted priority review to its application seeking expanded approval for its prostate cancer treatment ...